Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. Company
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products, an immunotherapy for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761), which is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which include Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S..
Sales per Business
20192020Delta
Cancer Immunotherapy0.14100%7.49100% +5255.8%
AUD in Million
Sales per region
20192020Delta
Australia0.14100%7.49100% +5255.8%
AUD in Million
Managers
Name Title Age Since
Marc Voigt Chief Executive Officer, CFO & Executive Director 47 2014
David Fang Finance Director & Assistant Secretary - 2018
Frédéric Triebel, Dr. Chief Scientific & Medical Officer 65 2014
Deanne Miller COO, Co-Secretary & General Counsel 43 2016
Russell John Howard, Dr. Non-Executive Chairman 70 2017
Peter A. Meyers Deputy Chairman 49 2017
Grant Chamberlain Independent Non-Executive Director 49 2017
Indira Naidu Joint Co-Secretary - 2021
Christian Mueller Vice President-Strategic Development - -
Members of the board
Name Title Age Since
Russell John Howard, Dr. Non-Executive Chairman 70 2017
Marc Voigt Chief Executive Officer, CFO & Executive Director 47 2014
Peter A. Meyers Deputy Chairman 49 2017
Grant Chamberlain Independent Non-Executive Director 49 2017
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 748,152,935 637,109,444 85.2% 0 0.0% 85.2%
Shareholders
NameEquities%
Australian Ethical Investments Ltd. (Investment Management) 41,583,333 4.89%
BlackRock Investment Management (UK) Ltd. 34,150,190 4.01%
FIL Investment Management (Hong Kong) Ltd. 32,355,237 3.80%
Perennial Value Management Ltd. 30,742,665 3.61%
BlackRock Advisors (UK) Ltd. 14,794,506 1.74%
Marc Voigt 8,791,695 1.03%
FIL Investment Management (Australia) Ltd. 7,743,928 0.91%
Frédéric Triebel 6,853,764 0.81%
Macenrock Pty Ltd. 3,622,897 0.43%
Lucinda Hughes Turnbull 2,981,626 0.35%
Company contact information
Immutep Ltd.
95 Pitt Street
Level 12
Sydney, New South Wales (NSW) 2000

Phone : +61.2.8315.7003
Fax : +61.2.8569.1880
Web : http://www.immutep.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Immutep Limited
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
IMMUTEP LIMITED30.12%341
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414
ALNYLAM PHARMACEUTICALS, INC.60.47%24 787
PHARMARON BEIJING CO., LTD.63.88%22 950
ICON PUBLIC LIMITED COMPANY41.06%21 917
HANGZHOU TIGERMED CONSULTING CO., LTD3.15%21 537
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.62.43%20 337
BIO-TECHNE CORPORATION56.83%19 541
PPD, INC.37.20%16 494
INCYTE CORPORATION-24.37%14 478
BACHEM HOLDING AG111.88%12 701
NOVAVAX, INC.45.23%12 063
QIAGEN N.V.-2.29%11 717
PRA HEALTH SCIENCES, INC.0.00%10 965
CUREVAC N.V.-50.88%10 301
INTELLIA THERAPEUTICS, INC.139.87%9 589
SYNEOS HEALTH, INC.28.74%9 077
Connections : Immutep Limited